secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001193125-25-168644
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track
--------------------------------------------------------------------------------

- Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.
- Revenue $8.7M in Q2 2025 vs $19.7M YoY; net loss $50.5M vs $32.9M YoY.
- WVE-006 AATD: multidose complete in 200mg cohort; 200mg data in 3Q 2025, 400mg data fall 2025.
- WVE-007 obesity: expanded Cohort 2 (240mg) to 32; data from Cohorts 1 and 2 expected 4Q 2025.
- Appointed Christopher Wright, MD, PhD, as Chief Medical Officer in May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/0001193125-25-168644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/d157278d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-168644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer